Q2 FY2026 EarningsQ2 FY2026 missed consensus on GAAP EPS, reporting -$0.36 vs. -$0.34 expected. Net loss of $22.4M was slightly wider than the $21.5M consensus, primarily due to unallocated internal costs despite a significant reduction in overall operating expenses following the 2025 restructuring. Revenue remains at zero as expected for this clinical-stage biopharmaceutical company. Key focus remains on the phase 1b FORTIFY trial for PLN-101095, which is progressing ahead of schedule with interim data expected in 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Pliant Therapeutics(PLRX) the EBIT is -23.86 M (+47.66%), Miss estimate;the EPS is -0.36 (+49.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B47.66%
-0.02B49.23%
-0.00B1.57%
EPSMiss expectations
-0.3649.30%
-0.337252.50%
-0.02283.20%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf